{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:36:56Z","timestamp":1785307016554,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01424-z","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:59:50Z","timestamp":1747213190000},"page":"1813-1831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient Experiences of Bullous Pemphigoid: Symptoms and Health-Related Quality of Life Impacts"],"prefix":"10.1007","volume":"15","author":[{"given":"Calvin N.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila","family":"Bahadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Yale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"1424_CR1","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1111\/jocd.14797","volume":"21","author":"L Lu","year":"2022","unstructured":"Lu L, Chen L, Xu Y, Liu A. Global incidence and prevalence of bullous pemphigoid: a systematic review and meta-analysis. J Cosmet Dermatol. 2022;21:4818\u201335. https:\/\/doi.org\/10.1111\/jocd.14797.","journal-title":"J Cosmet Dermatol"},{"key":"1424_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/jdv.15883","volume":"34","author":"Y Ben Mordehai","year":"2020","unstructured":"Mordehai YB, Faibish H, Astman N, et al. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid. J Eur Acad Dermatol Venereol. 2020;34:161\u20135. https:\/\/doi.org\/10.1111\/jdv.15883.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1424_CR3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","volume":"167","author":"R della Torre","year":"2012","unstructured":"della Torre R, Combescure C, Cort\u00e9s B, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol. 2012;167:1111\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11108.x.","journal-title":"Br J Dermatol"},{"key":"1424_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/1346-8138.15111","volume":"46","author":"H Ujiie","year":"2019","unstructured":"Ujiie H, Iwata H, Yamagami J, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol. 2019;46:1102\u201335. https:\/\/doi.org\/10.1111\/1346-8138.15111.","journal-title":"J Dermatol"},{"key":"1424_CR5","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36:1689\u2013704. https:\/\/doi.org\/10.1111\/jdv.18220.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1424_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","volume":"155","author":"K Kridin","year":"2019","unstructured":"Kridin K, Bergman R. Assessment of the prevalence of mucosal involvement in bullous pemphigoid. JAMA Dermatol. 2019;155:166\u201371. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5049.","journal-title":"JAMA Dermatol"},{"key":"1424_CR7","doi-asserted-by":"publisher","first-page":"adv00224","DOI":"10.2340\/00015555-3457","volume":"100","author":"MJ Verheyden","year":"2020","unstructured":"Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol. 2020;100:adv00224. https:\/\/doi.org\/10.2340\/00015555-3457.","journal-title":"Acta Derm Venereol"},{"key":"1424_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/ccid.S267573","volume":"15","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Megna M, Villani A, et al. Strategies to improve outcomes of bullous pemphigoid: a comprehensive review of clinical presentations, diagnosis, and patients\u2019 assessment. Clin Cosmet Investig Dermatol. 2022;15:661\u201373. https:\/\/doi.org\/10.2147\/ccid.S267573.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1424_CR9","doi-asserted-by":"publisher","first-page":"100129","DOI":"10.1016\/j.xjidi.2022.100129","volume":"2","author":"M Guignant","year":"2022","unstructured":"Guignant M, Tedbirt B, Murrell DF, et al. How do experts treat patients with bullous\u00a0pemphigoid around the world? An\u00a0international survey. JID Innov. 2022;2:100129. https:\/\/doi.org\/10.1016\/j.xjidi.2022.100129.","journal-title":"JID Innov."},{"key":"1424_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/07853890.2018.1443346","volume":"50","author":"Y Wang","year":"2018","unstructured":"Wang Y, Mao X, Wang Y, et al. Relapse of bullous pemphigoid: an update on this stubborn clinical problem. Ann Med. 2018;50:234\u20139. https:\/\/doi.org\/10.1080\/07853890.2018.1443346.","journal-title":"Ann Med"},{"key":"1424_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/ddg.14852","volume":"20","author":"IH Huang","year":"2022","unstructured":"Huang IH, Wu PC, Liu CW, Huang YC. Association between bullous pemphigoid and psychiatric disorders: a systematic review and meta-analysis. J Dtsch Dermatol Ges. 2022;20:1305\u201312. https:\/\/doi.org\/10.1111\/ddg.14852.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1424_CR12","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jdv.13660","volume":"30","author":"YC Lai","year":"2016","unstructured":"Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30:2007\u201315. https:\/\/doi.org\/10.1111\/jdv.13660.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1424_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ajd.12764","volume":"59","author":"RJ Lucariello","year":"2018","unstructured":"Lucariello RJ, Villablanca SE, Mascar\u00f3 JM Jr, Reichel M. Association between bullous pemphigoid and malignancy: a meta-analysis. Australas J Dermatol. 2018;59:253\u201360. https:\/\/doi.org\/10.1111\/ajd.12764.","journal-title":"Australas J Dermatol."},{"key":"1424_CR14","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1111\/ajd.14355","volume":"65","author":"K Kridin","year":"2024","unstructured":"Kridin K, Goychberg R, Kridin M, et al. The cardiovascular risk in bullous pemphigoid: Insights from a population-based study. Australas J Dermatol. 2024;65:e187\u201393. https:\/\/doi.org\/10.1111\/ajd.14355.","journal-title":"Australas J Dermatol."},{"key":"1424_CR15","doi-asserted-by":"publisher","first-page":"1427943","DOI":"10.3389\/fimmu.2024.1427943","volume":"15","author":"LY Yang","year":"2024","unstructured":"Yang LY, Wang YL, Zuo YG. Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment. Front Immunol. 2024;15:1427943. https:\/\/doi.org\/10.3389\/fimmu.2024.1427943.","journal-title":"Front Immunol"},{"key":"1424_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/ajd.12899","volume":"60","author":"K Phan","year":"2019","unstructured":"Phan K, Goyal S, Murrell DF. Association between bullous pemphigoid and psoriasis: systematic review and meta-analysis of case-control studies. Australas J Dermatol. 2019;60:23\u20138. https:\/\/doi.org\/10.1111\/ajd.12899.","journal-title":"Australas J Dermatol."},{"key":"1424_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.det.2011.06.003","volume":"29","author":"BS Daniel","year":"2011","unstructured":"Daniel BS, Borradori L, Hall RP, Murrell DF. Evidence-based management of bullous pemphigoid. Dermatol Clin. 2011;29:613\u201320. https:\/\/doi.org\/10.1016\/j.det.2011.06.003.","journal-title":"Dermatol Clin"},{"key":"1424_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/jdv.12153","volume":"28","author":"JB Terra","year":"2014","unstructured":"Terra JB, Potze WJ, Jonkman MF. Whole body application of a potent topical corticosteroid for bullous pemphigoid. J Eur Acad Dermatol Venereol. 2014;28:712\u20138. https:\/\/doi.org\/10.1111\/jdv.12153.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1424_CR19","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/jvc2.444","volume":"3","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Yang F, Alemao E, et al. Risk of adverse events in patients with bullous pemphigoid treated with oral corticosteroids in the United States. JEADV Clin Pract. 2024;3:1206\u201311. https:\/\/doi.org\/10.1002\/jvc2.444.","journal-title":"JEADV Clin Pract."},{"key":"1424_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","volume":"25","author":"M Karakioulaki","year":"2024","unstructured":"Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update. Am J Clin Dermatol. 2024;25:195\u2013212. https:\/\/doi.org\/10.1007\/s40257-023-00832-1.","journal-title":"Am J Clin Dermatol"},{"key":"1424_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jdin.2022.07.005","volume":"9","author":"FAP Zeng","year":"2022","unstructured":"Zeng FAP, Wilson A, Sheriff T, Murrell DF. Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: a systematic review. JAAD Int. 2022;9:33\u201343. https:\/\/doi.org\/10.1016\/j.jdin.2022.07.005.","journal-title":"JAAD Int."},{"key":"1424_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1590\/abd1806-4841.20164935","volume":"91","author":"A Kouris","year":"2016","unstructured":"Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study. An Bras Dermatol. 2016;91:601\u20133. https:\/\/doi.org\/10.1590\/abd1806-4841.20164935.","journal-title":"An Bras Dermatol"},{"key":"1424_CR23","doi-asserted-by":"publisher","first-page":"adv00320","DOI":"10.2340\/00015555-3683","volume":"100","author":"C Briand","year":"2020","unstructured":"Briand C, Gourier G, Poizeau F, et al. Characteristics of pruritus in bullous pemphigoid and impact on quality of life: a prospective cohort study. Acta Derm Venereol. 2020;100:adv00320. https:\/\/doi.org\/10.2340\/00015555-3683.","journal-title":"Acta Derm Venereol"},{"key":"1424_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/njcp.njcp_216_19","volume":"23","author":"A Bilgic","year":"2020","unstructured":"Bilgic A, Aydin F, Sumer P, et al. Oral health related qual\u0131ty of l\u0131fe and d\u0131sease sever\u0131ty \u0131n auto\u0131mmune bullous d\u0131seases. Niger J Clin Pract. 2020;23:159\u201364. https:\/\/doi.org\/10.4103\/njcp.njcp_216_19.","journal-title":"Niger J Clin Pract"},{"key":"1424_CR25","doi-asserted-by":"publisher","first-page":"e004","DOI":"10.1097\/jw9.0000000000000004","volume":"8","author":"A Behkar","year":"2022","unstructured":"Behkar A, Garmaroudi G, Nasimi M, et al. Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of treatment of autoimmune bullous disease quality of life questionnaire finds similar effects in women as men. Int J Womens Dermatol. 2022;8:e004. https:\/\/doi.org\/10.1097\/jw9.0000000000000004.","journal-title":"Int J Womens Dermatol."},{"key":"1424_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Val Health. 2011;14:967\u201377. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014.","journal-title":"Val Health"},{"key":"1424_CR27","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2013assessing respondent understanding. Val Health. 2011;14:978\u201388. https:\/\/doi.org\/10.1016\/j.jval.2011.06.013.","journal-title":"Val Health"},{"key":"1424_CR28","first-page":"66","volume":"29","author":"K Kulthanan","year":"2011","unstructured":"Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol. 2011;29:66\u201372.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"1424_CR29","doi-asserted-by":"publisher","first-page":"A456","DOI":"10.1016\/S1098-3015(10)65572-6","volume":"10","author":"D Wild","year":"2007","unstructured":"Wild D, Donatti C, Hareendran A. PMC18 The role of conceptual models, endpoint models, and conceptual frameworks when making treatment benefit claims to the FDA. Val Health. 2007;10:A456. https:\/\/doi.org\/10.1016\/S1098-3015(10)65572-6.","journal-title":"Val Health"},{"key":"1424_CR30","first-page":"9","volume":"14","author":"C Donatti","year":"2008","unstructured":"Donatti C, Wild D, Hareendran A. The use of conceptual models, conceptual frameworks, and endpoint models to support label claims of treatment benefit using patient reported outcomes. ISPOR Connect. 2008;14:9\u201312.","journal-title":"ISPOR Connect."},{"key":"1424_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/jpd-202457","volume":"12","author":"H Staunton","year":"2022","unstructured":"Staunton H, Kelly K, Newton L, et al. A patient-centered conceptual model of symptoms and their impact in early parkinson\u2019s disease: a qualitative study. J Parkinsons Dis. 2022;12:137\u201351. https:\/\/doi.org\/10.3233\/jpd-202457.","journal-title":"J Parkinsons Dis"},{"key":"1424_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/0272989x16662009","volume":"37","author":"M Tabberer","year":"2017","unstructured":"Tabberer M, Gonzalez-McQuire S, Muellerova H, et al. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Making. 2017;37:440\u201352. https:\/\/doi.org\/10.1177\/0272989x16662009.","journal-title":"Med Decis Making"},{"key":"1424_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.36469\/001c.82228","volume":"10","author":"L Broderick","year":"2023","unstructured":"Broderick L, Chen WH, Levy RA, et al. Development of a conceptual model to understand disease burden in patients with systemic lupus erythematosus and organ damage. J Health Econ Outcomes Res. 2023;10:30\u20138. https:\/\/doi.org\/10.36469\/001c.82228.","journal-title":"J Health Econ Outcomes Res."},{"key":"1424_CR34","doi-asserted-by":"publisher","unstructured":"Kluger N, Pankakoski A, Panelius J. Depression and anxiety in patients with bullous pemphigoid: impact and management challenges. Clin Cosmet Investig Dermatol. 2020;13:73\u20136. https:\/\/doi.org\/10.2147\/ccid.S212984.","DOI":"10.2147\/ccid.S212984"},{"key":"1424_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jdin.2023.04.014","volume":"13","author":"HA Stirnadel-Farrant","year":"2023","unstructured":"Stirnadel-Farrant HA, Xu X, Kwiatek J, et al. Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: a retrospective analysis of US health insurance claims data. JAAD Int. 2023;13:117\u201325. https:\/\/doi.org\/10.1016\/j.jdin.2023.04.014.","journal-title":"JAAD Int"},{"key":"1424_CR36","doi-asserted-by":"publisher","unstructured":"Bilgic A, Murrell DF. Toxicity of glucocorticosteroids in autoimmune blistering diseases. Mucosa. 2019;2:59\u201367. https:\/\/doi.org\/10.33204\/mucosa.607952.","DOI":"10.33204\/mucosa.607952"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01424-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01424-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01424-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T10:00:03Z","timestamp":1748685603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01424-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01424-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Calvin N. Ho and Lila Bahadori are employees of AstraZeneca and may own stock\/stock options. Marc Yale and Naomi Bishop have nothing to disclose. Caroline Roberts, Oren Meyers, and Julie Bailey are or were employees of IQVIA at the time of the study, which received funding from AstraZeneca for the conduct of this study; Caroline Roberts is currently an employee of Blue Fin Group, an IntegriChain Company, and Oren Meyers is currently an employee of GSK. Neil J. Korman has been an investigator for Abcentra, Amgen, Castle Bioscience, Celgene, Chemocentryx, Galderma, Kyowa Hakko Kirin Pharma, Menlo Therapeutics, and XBiotech; advisory board member for Boehringer Ingelheim and Sun Pharma; investigator and advisory board member for Argenx, Bristol Myers Squibb, Dermavant, Leo Pharma, Principia, Regeneron, Trevi, and UCB; investigator, advisory board member, and speaker for AbbVie and Eli Lilly; consultant for AstraZeneca; advisory board member and speaker for Janssen; and advisory board member, speaker, and consultant for Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was granted Institutional Review Board approval from WCG Clinical, Inc (approval number: 20220923), and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}